Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells

Molecular Pharmacology

Volumn 66, Issue 5, 2004, Pages 1332-1339

  Troost, Joachim ^a   Lindenmaier, Heike ^a   Haefeli, Walter Emil ^a   Weiss, Johanna ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM;

ANIMALS; BIOLOGICAL TRANSPORT; BORON COMPOUNDS; CAVEOLIN 1; CAVEOLINS; CHOLESTEROL; DRUG RESISTANCE, NEOPLASM; HUMANS; LLC-PK1 CELLS; P-GLYCOPROTEIN; SWINE; VERAPAMIL;

EID: 6944256675     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.002329     Document Type: Article

References (41)

1. Arima H, Yunomae K, Hirayama F, and Uekama K (2001) Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. J Pharmacol Exp Ther 297:547-555.
2. Brown DA and London E (1998) Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 14:111-136.
3. Chiou WL, Chung SM, and Wu TC (2000) Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 17:903-905.
4. Demeule M, Jodoin J, Gingras D, and Beliveau R (2000) P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett 466:219-224.
5. Fastenberg ME, Shogomori H, Xu X, Brown DA, and London E (2003) Exclusion of a transmembrane-type peptide from ordered-lipid domains (rafts) detected by fluorescence quenching: extension of quenching analysis to account for the effects of domain size and domain boundaries. Biochemistry 42:12376-12390.
6. Garrigues A, Escargueil AE, and Orlowski S (2002) The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci USA 99:10347-10352.
7. Ghetie MA, Marches R, Kufert S, and Vitetta ES (2004) An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-glycoprotein) and CD19, causes P-glycoprotein to translocate out of lipid rafts and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line. Blood 104:178-183.
8. Gimpl G, Burger K, and Fahrenholz F (1997) Cholesterol as modulator of receptor function. Biochemistry 36:10959-10974.
9. Gottesman MM, Fojo T, and Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
10. Klein U, Gimpl G, and Fahrenholz F (1995) Alteration of the myometrial plasma membrane cholesterol content with beta-cyclodextrin modulates the binding affinity of the oxytocin receptor. Biochemistry 34:13784-13793.
11. Kusuhara H, Suzuki H, and Sugiyama Y (1998) The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J Pharm Sci 87:1025-1040.
12. Lavie Y, Fiucci G, and Liscovitch M (1998) Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 273:32380-32383.
13. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, and Dey S (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
14. Lelong IH, Guzikowski AP, Haugland RP, Pastan I, Gottesman MM, and Willingham MC (1991) Fluorescent verapamil derivative for monitoring activity of the multidrug transporter. Mol Pharmacol 40:490-494.
15. Liscovitch M and Lavie Y (2000) Multidrug resistance: a role for cholesterol efflux pathways? Trends Biochem Sci 25:530-534.
16. London E and Brown DA (2000) Insolubility of lipids in triton X-100: physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim Biophys Acta 1508:182-195.
17. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
18. Luker GD, Pica CM, Kumar AS, Covey DF, and Piwnica-Worms D (2000) Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains. Biochemistry 39:8692.
19. Pallarés-Trujillo J, Domènech C, Grau-Oliete MR, and Rivera-Fillat MP (1993) Role of cell cholesterol in modulating vincristine uptake and resistance. Int J Cancer 55:667-671.
20. Pike LJ and Casey L (2002) Cholesterol levels modulate EGF receptor-mediated signaling by altering receptor function and trafficking. Biochemistry 41:10315-10322.
21. Pohl A, Lage H, Muller P, Pomorski T, and Herrmann A (2002) Transport of phosphatidylserine via MDR1 (multidrug resistance 1) P-glycoprotein in a human gastric carcinoma cell line. Biochem J 365:259-268.
22. Razani B, Woodman SE, and Lisanti MP (2002) Caveolae: from cell biology to animal physiology. Pharmacol Rev 54:431-467.
23. Regev R, Assaraf YG, and Eytan GD (1999) Membrane fluidization by ether, other anesthetics and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem 259:18-24.
24. Romsicki Y and Sharom FJ (1999) The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 38:6887-6896.
25. Romsicki Y and Sharom FJ (2001) Phospholipid flippase activity of the reconstituted P-glycoprotein multidrug transporter. Biochemistry 40:6937-6947.
26. Rothnie A, Theron D, Soceneantu L, Martin C, Traikia M, Berridge G, Higgins CF, Devaux PF, and Callaghan R (2001) The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence. Eur Biophys J 30:430-442.
27. Saeki T, Shimabuku AM, Ueda K, and Komano T (1992) Specific drug binding by purified lipid-reconstituted P-glycoprotein: dependence on the lipid composition. Biochim Biophys Acta 1107:105-110.
28. Schinkel AH and Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29.
29. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, Van Der Valk MA, Robanus-Maandag EC, te Riele HP, et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
30. Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Investig 97:2517-2524.
31. Simons K and Toomre D (2000) Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1:31-39.
32. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, and Brasitus TA (1992) Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem 267:24995-25002.
33. Smart EJ and Anderson RG (2002) Alterations in membrane cholesterol that affect structure and function of caveolae. Methods Enzymol 353:131-139.
34. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, Chu C, Kohtz DS, and Lisanti MP (1996) Expression of caveolin-3 in skeletal, cardiac and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem 271:15160-15165.
35. Sprong H, van der Sluijs SP, and van Meer G (2001) How proteins move lipids and lipids move proteins. Nat Rev Mol Cell Biol 2:504-513.
36. Troost J, Albermann N, Haefeli WE, and Weiss J (2004) Cholesterol modulates P-glycoprotein activity in human peripheral blood mononuclear cells. Biochem Biophys Res Commun 316:705-711.
37. van Asperen J, van Tellingen O, and Beijnen JH (1998) The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 37:429-435.
38. van Meer G (2002) Cell biology. The different hues of lipid rafts. Science (Wash DC) 296:855-857.
39. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, and Haefeli WE (2003a) Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305:197-204.
40. Weiss J, Kerpen CJ, Lindenmaier H, Dormann SM, and Haefeli WE (2003b) Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 307:262-267.
41. Yunomae K, Arima H, Hirayama F, and Uekama K (2003) Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett 536:225-231.